Search

Your search keyword '"Kandziora, Christian"' showing total 10 results
Start Over Author "Kandziora, Christian"
10 results on '"Kandziora, Christian"'

1. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

Author

Klement, Piroska, Fiedler, Walter, Gabdoulline, Razif, Dallmann, Louisa-Kristin, Wienecke, Clara Philine, Schiller, Johannes, Kandziora, Christian, Teich, Katrin, Heida, Bennett, Büttner, Konstantin, Brandes, Maximilian, Funke, Carolin, Wichmann, Martin, Othman, Basem, Chromik, Joerg, Amberg, Stefanie, Kebenko, Maxim, Schlipfenbacher, Vera, Wilke, Anne Christine, Modemann, Franziska, Janning, Melanie, Serve, Hubert, Bokemeyer, Carsten, Theile, Susann, Deppermann, Ute, Kranich, Anne L., Ganser, Arnold, Thol, Felicitas, and Heuser, Michael

Published
2023
Full Text
View/download PDF

2. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML

Author

Thol, Felicitas, Gabdoulline, Razif, Liebich, Alessandro, Klement, Piroska, Schiller, Johannes, Kandziora, Christian, Hambach, Lothar, Stadler, Michael, Koenecke, Christian, Flintrop, Madita, Pankratz, Mira, Wichmann, Martin, Neziri, Blerina, Büttner, Konstantin, Heida, Bennet, Klesse, Sabrina, Chaturvedi, Anuhar, Kloos, Arnold, Göhring, Gudrun, Schlegelberger, Brigitte, Gaidzik, Verena I., Bullinger, Lars, Fiedler, Walter, Heim, Albert, Hamwi, Iyas, Eder, Matthias, Krauter, Jürgen, Schlenk, Richard F., Paschka, Peter, Döhner, Konstanze, Döhner, Hartmut, Ganser, Arnold, and Heuser, Michael

Published
2018
Full Text
View/download PDF

3. Molecular response patterns in relapsed/refractory AML patients treated with selinexor and chemotherapy

Author

Klement, Piroska, primary, Fiedler, Walter, additional, Gabdoulline, Razif, additional, Dallmann, Louisa-Kristin, additional, Wienecke, Clara Philine, additional, Schiller, Johannes, additional, Kandziora, Christian, additional, Teich, Katrin, additional, Heida, Bennett, additional, Büttner, Konstantin, additional, Brandes, Maximilian, additional, Funke, Carolin, additional, Wichmann, Martin, additional, Othman, Basem, additional, Chromik, Joerg, additional, Amberg, Stefanie, additional, Kebenko, Maxim, additional, Schlipfenbacher, Vera, additional, Wilke, Anne Christine, additional, Modemann, Franziska, additional, Janning, Melanie, additional, Serve, Hubert, additional, Bokemeyer, Carsten, additional, Theile, Susann, additional, Deppermann, Ute, additional, Kranich, Anne L., additional, Ganser, Arnold, additional, Thol, Felicitas, additional, and Heuser, Michael, additional

Published
2022
Full Text
View/download PDF

4. Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy

Author

Klement, Piroska, primary, Fiedler, Walter, additional, Gabdoulline, Razif, additional, Dallmann, Louisa-Kristin, additional, Wienecke, Clara, additional, Schiller, Johannes, additional, Kandziora, Christian, additional, Teich, Katrin, additional, Heida, Bennet, additional, Brandes, Maximilian, additional, Funke, Carolin, additional, Wichmann, Martin, additional, Othman, Basem, additional, Chromik, Jörg, additional, Büttner, Konstantin, additional, Amberg, Stefanie, additional, Kebenko, Maxim, additional, Schlipfenbacher, Vera, additional, Wilke, Anne C, additional, Modemann, Franziska, additional, Janning, Melanie, additional, Serve, Hubert, additional, Bokemeyer, Carsten, additional, Deppermann, Ute, additional, Kranich, Anne L., additional, Ganser, Arnold, additional, Thol, Felicitas, additional, and Heuser, Michael, additional

Published
2021
Full Text
View/download PDF

5. Impact ofPPM1Dmutations in patients with myelodysplastic syndrome and deletion of chromosome 5q

Author

Panagiota, Victoria, primary, Meggendorfer, Manja, additional, Kubasch, Anne Sophie, additional, Gabdoulline, Razif, additional, Krönke, Jan, additional, Mies, Anna, additional, Shahswar, Rabia, additional, Kandziora, Christian, additional, Klement, Piroska, additional, Schiller, Johannes, additional, Göhring, Gudrun, additional, Haferlach, Claudia, additional, Ganster, Christina, additional, Shirneshan, Katayoon, additional, Gutermuth, Annika, additional, Thiede, Christian, additional, Germing, Ulrich, additional, Schroeder, Thomas, additional, Kobbe, Guido, additional, Klesse, Sabrina, additional, Koenecke, Christian, additional, Schlegelberger, Brigitte, additional, Kröger, Nicolaus, additional, Haase, Detlef, additional, Döhner, Konstanze, additional, Sperr, Wolfgang R., additional, Valent, Peter, additional, Ganser, Arnold, additional, Thol, Felicitas, additional, Haferlach, Torsten, additional, Platzbecker, Uwe, additional, and Heuser, Michael, additional

Published
2021
Full Text
View/download PDF

6. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.

Author

Panagiota, Victoria, Meggendorfer, Manja, Kubasch, Anne Sophie, Gabdoulline, Razif, Krönke, Jan, Mies, Anna, Shahswar, Rabia, Kandziora, Christian, Klement, Piroska, Schiller, Johannes, Göhring, Gudrun, Haferlach, Claudia, Ganster, Christina, Shirneshan, Katayoon, Gutermuth, Annika, Thiede, Christian, Germing, Ulrich, Schroeder, Thomas, Kobbe, Guido, and Klesse, Sabrina

Published
2021
Full Text
View/download PDF

7. The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

Author

Panagiota, Victoria, primary, Meggendorfer, Manja, additional, Kubasch, Anne Sophie, additional, Gabdoulline, Razif, additional, Krönke, Jan, additional, Shahswar, Rabia, additional, Mies, Anna, additional, Kandziora, Christian, additional, Klement, Piroska, additional, Schiller, Johannes, additional, Göhring, Gudrun, additional, Haferlach, Claudia, additional, Ganster, Christina, additional, Shirneshan, Katayoon, additional, Gutermuth, Annika, additional, Thiede, Christian, additional, Germing, Ulrich, additional, Schroeder, Thomas, additional, Kobbe, Guido, additional, Klesse, Sabrina, additional, Koenecke, Christian, additional, Schlegelberger, Brigitte, additional, Kroeger, Nicolaus, additional, Haase, Detlef, additional, Döhner, Konstanze, additional, Sperr, Wolfgang R., additional, Valent, Peter, additional, Ganser, Arnold, additional, Thol, Felicitas, additional, Haferlach, Torsten, additional, Platzbecker, Uwe, additional, and Heuser, Michael, additional

Published
2018
Full Text
View/download PDF

8. The Role of PPM1DMutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q

Author

Panagiota, Victoria, Meggendorfer, Manja, Kubasch, Anne Sophie, Gabdoulline, Razif, Krönke, Jan, Shahswar, Rabia, Mies, Anna, Kandziora, Christian, Klement, Piroska, Schiller, Johannes, Göhring, Gudrun, Haferlach, Claudia, Ganster, Christina, Shirneshan, Katayoon, Gutermuth, Annika, Thiede, Christian, Germing, Ulrich, Schroeder, Thomas, Kobbe, Guido, Klesse, Sabrina, Koenecke, Christian, Schlegelberger, Brigitte, Kroeger, Nicolaus, Haase, Detlef, Döhner, Konstanze, Sperr, Wolfgang R., Valent, Peter, Ganser, Arnold, Thol, Felicitas, Haferlach, Torsten, Platzbecker, Uwe, and Heuser, Michael

Abstract

Background:PPM1Dis a serine/threonine phosphatase that inactivates p53 tumor suppressor pathway. Recently, PPM1Dmutations have been described in clonal hematopoiesis and are more frequently found in therapy-related MDS than in primary MDS (15% vs. 3%). Del(5q), is the most prevalent cytogenetic abnormality in MDS. A high proportion of MDS del(5q) patients respond to lenalidomide, but almost 40% of them progress to AML. Scharenberg et al. identified recurrent mutations in a limited number of genes i.e. TP53, RUNX1, and TET2in a longitudinal cohort of 35 MDS del(5q) patients that progressed to AML. The clinical impact and occurrence of PPM1Dmutations in MDS del(5q) patients remains unknown.

Published
2018
Full Text
View/download PDF

9. PPM1DMutations in MDS Patients with Deletion of Chromosome 5q

Author

Panagiota, Victoria, Meggendorfer, Manja, Shahswar, Rabia, Kandziora, Christian, Klement, Piroska, Schiller, Johannes, Göhring, Gudrun, Krönke, Jan, Haferlach, Claudia, Ganster, Christina, Shirneshan, Katayoon, Gutermuth, Annika, Platzbecker, Uwe, Thiede, Christian, Germing, Ulrich, Schroeder, Thomas, Kobbe, Guido, Klesse, Sabrina, Koenecke, Christian, Schlegelberger, Brigitte, Kröger, Nicolaus, Haase, Detlef, Dohner, Konstanze, Sperr, Wolfgang R., Valent, Peter, Ganser, Arnold, Thol, Felicitas, Haferlach, Torsten, and Heuser, Michael

Abstract

Background:Patients with myelodysplastic syndrome with deletion of chromosome 5q (MDS del(5q)) have a favorable prognosis, but TP53mutations occur in 13-18% of these patients and are known as unfavorable prognostic marker. Recently, Protein Phosphatase Magnesium-Dependent 1 (PPM1D) mutations have been described in clonal hematopoiesis and were found more commonly in patients with therapy-related MDS than in patients with primary MDS (15% vs. 3%) (Lindsley et al. 2017). PPM1Dencodes a serine-threonine protein phosphatase that inhibits the p53 tumor suppressor pathway. It is therefore of great interest to evaluate the frequency and potential co-occurrence of PPM1Dmutations in patients with MDS del(5q).

Published
2017
Full Text
View/download PDF

10. Next-Generation Sequencing-Based Measurable Residual Disease (MRD) Monitoring Is Highly Predictive for Outcome after Allogeneic Stem Cell Transplantation

Author

Thol, Felicitas, Liebich, Alessandro, Gabdoulline, Razif, Klement, Piroska, Schiller, Johannes, Kandziora, Christian, Flintrop, Madita, Pankratz, Mira, Wichmann, Martin, Neziri, Blerina, Klesse, Sabrina, Chaturvedi, Anuhar, Kloos, Arnold, Gaidzik, Verena I., Paschka, Peter, Bullinger, Lars, Fiedler, Walter, Heim, Albert, Hambach, Lothar, Stadler, Michael, Hamwi, Iyas, Eder, Matthias, Krauter, Jürgen, Schlenk, Richard F., Dohner, Konstanze, Döhner, Hartmut, Ganser, Arnold, and Heuser, Michael

Abstract

Background:Molecular predictors for relapse following allogeneic haematopoietic stem cell transplantation (alloHSCT) are urgently needed as 30-40% of AML patients experience recurrence of disease after HSCT. Measurable residual disease monitoring (MRD) for nucleophosmin 1 (NPM1) mutations has proven to be highly predictive for relapse in AML patients treated with or without alloHSCT. However, the majority of AML patients undergoing alloHSCT do not have the favorable NPM1marker so that alternative markers and techniques are required. We studied a next-generation sequencing (NGS)-based error-corrected sequencing approach that is applicable to all mutations for its ability to prognosticate relapse and survival following alloHSCT.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results